Drug-Induced liver disease

Drug-Induced Liver Disease

Volumn , Issue , 2002, Pages 519-548

  Bonacini, Maurizio ^a   Louie, Stan ^b   Weissman, Kevin ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c KING DREW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052569942     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (162)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patient with advanced human immunodeficiency virus infection. N Engl J Med 1998; 448:854-860.
2. Temesgen Z, Wright AJ. Antiretrovirals. Mayo Clin Proc 1999; 74:1284-1401.
3. Mauskopf JA, Tolson JM, Simpson KN, et al. Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J AIDS 2000; 23:302-313.
4. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the US. N Engl J Med 1999; 341(17):1256-1263.
5. Gilson RJC, Chopra K, Newell AM, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Vir Hep 1999; 6(5):387-395.
6. Alter MJ, Kruszon-Moran D, Nainan OV, et al. Prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
7. Liang TJ. Combination therapy for hepatitis C infection. N Engl J Med 1998; 339:1549.
8. Manns M, McHutchison JG, Gordon S, et al. Peginterferon alfa-2B plus ribavirin compared to interferon alfa-2B plus ribavirin for the treatment of chronic hepatitis C: 24-week treatment analysis of a multicenter multinational phase III randomized controlled trial. Hepatology 2000; 32:297A.
9. Trepo C, Lindsay K, Niederau C, et al. Pegylated interferon ALFA-2B (PEG-Intron) monotherapy is superior to Interferon ALFA-2b (INTRON A) for the treatment of chronic hepatitis. J Hepatol 2000; 32(suppl 2):29.
10. Hayden FG. Update on influenza and rhinovirus infections. Adv Exp Med Biol 1999; 458: 55-76.
11. Wood AJJ. Thrombotic thrombocytopenic purpura and clopidogrel-a need for new approaches to drug safety. N Engl J Med 2000; 342:1824-1826.
12. Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32(suppl 1):77-82.
13. Styrt B, Freiman JP. Hepatoxicity of antiviral drugs. Gastrointest Clin North Am 1995; 24: 839-852.
14. Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Safety 1997; 16:1-8.
15. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157:1871-1876.
16. Saliba B, Herbert PN. Oxacillin hepatotoxicity in HIV-infected patients [letter]. Ann Intern Med 1994; 120:1048.
17. DeLeve L, Kaplowitz N. Mechanisims of drug-induced liver disease. Gastroenterol Clin North Am 1995; 24(4):787-810.
18. Zimmermann HJ. The spectrum of hepatotoxicity. In: HJ Zimmermann, ed. Hepatotoxicity. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins, 1999.
19. Tanaka E. Update: genetic polymorphism of drug metabolizing enzymes in humans. J Clin Pharm Ther 1999; 24:424-429.
20. Physicians’ Desk Reference. 54th ed. Montclair, NJ: Medical Economics, 2000.
21. Drug Facts and Comparisons. 54th ed. St Louis, MO: Facts and Comparisons, 1999.
22. Barry M, Mulachy F, Merry C, Gibbions S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infections. Clin Phamaco-kinet 1999; 36(4):289-304.
23. Bartlett JG, Gallant JE. 2000-2001 Medical Management of HIV Infection. Baltimore: Johns Hopkins University, 2000:81-89.
24. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 2000; 32:39-47.
25. Holazo AA, Winkler MB, Patel IH. Effects of age, gender, and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharm 1988; 28:1040-1045.
26. Mayersohn M. Considerations in the elderly. In: WE Evans, JJ Schentag, W Juska, eds. Applied Pharmakotherapeutics. 3rd ed. Vancouver, WA: 1992.
27. Hunt C, Westerkam W, Stave G. Effects of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44(2):275-283.
28. Fletcher CV, Acosta EP, Strykoski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 1994; 15:619-629.
29. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24:339-346.
30. Kashuba AD, Bertino JS, Rocci ML, et al. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998; 64:269-277.
31. Miners JO, Robson RA, Birkett DJ. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects of clofibric acid elimination. Br J Clin Pharmacol 1984; 18: 240-243.
32. Villani P, Regazzi MB, Castelli F. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-I infected patients. Br J Clin Pharmacol 1999; 48:712-715.
33. Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol 1999; 41:1098-1105.
34. Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch Intern Med 2000; 160:3365-3373.
35. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIV-infected patients. J Hepatol 1997; 27:18-24.
36. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine cohort, France, 19961998. AIDS 1999; 13:F115-F121.
37. Sulkowski M, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 284:74-80.
38. Ookhtens M, Kaplowitz N. Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. Semin Liver Dis 1998; 18:414-429.
39. Barbaro G, DiLorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999; 94:2198-2205.
40. Loguercio C, Clot P, Albano E, et al. Free radicals and not acetaldehyde influence the circulating levels of glutathione after acute or chronic alcohol abuse in vivo and in vitro studies. Ital J Gastroenterol Hepatol 1997; 29:168-173.
41. Barbaro G, Di Lorenzo G, Soldini M, et al. Hepatic glutathione in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasma and lymphocytic concentrations and with the activity of liver disease. Am J Gastroenterol 1996; 91:2569-2574.
42. Larrey, D, Pageaux P. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26(suppl 2);12-21.
43. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997; 94:1967-1972.
44. Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, Wells PG. Oxidative stress and thiol-disulfide depletion in plasma and peripheral blood lymphocytes from HIV infected patients: toxicological and pharmacological implications. AIDS 1997; 11:1689-1697.
45. De Rosa SC, Zaretsky MD, Dubs JG, et al. V-Acetylcysteine replenished glutathione in HIV infection. Eur J Clin Invest 2000; 30:915-929.
46. Choi J, Liu RM, Kundu RK, et al. Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice. J Biol Chem 2000; 275:4694-4698.
47. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis: effects of drugs, ethanol, hormones, and cytokines. J Hepatol 1997; 26:43-53.
48. 47a. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J AIDS 2001; 27: 426-431.
49. Fernadez-Checa JC, Kaplowitz N, Garcia-Ruiz C, et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997; 274:G7-G17.
50. Smith SR, Boyd EL, Kirking DM. Nonprescription and alternative medication use by individuals with HIV disease. Ann Pharmacother 1999; 44:294-400.
51. Strader D, Bacon B, Hoofnagle J, LaBrecque D, Morgan T, Lindsay K. Use of CAM by patients in liver disease clinics [abstract]. Natcher Conference Center, Bethesda, MD, August 1999.
52. Ostrow MJ, Cornelisse PGA, Heath KV, et al. Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents. J AIDS 1997; 15:115-120.
53. Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med 1998; 158:2257-2264.
54. McKnight I, Scott M. Managing HIV: HIV and complementary medicine. Med J Aust 1996; 165:144-145.
55. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John’s wort. Lancet 2000; 355:547-548.
56. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J AIDS 2000; 23(3):236-245.
57. Arribas JR, Ibanez C, Ruiz-Antoran B, et al. Acute hepatitis in HIV-infected patients during ritonavir treatment. AIDS 1998; 12:1722-1724.
58. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14(3):F25-32.
59. McKenzie M, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU) an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 444:1099-1105.
60. Arnaudo E, Dalakas M, Shanke S, et al. Depletion of muscle mitochondria DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 447:508-510.
61. Styrt BA, Piazza-Hepp TD, Chikami GK. Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Res 1996; 41:121-145.
62. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nature Med 1995; 1:417-422.
63. Rusanen H, Majamaa K, Hassinen IE. Increased activities of antioxidant enzymes and decreased ATP concentration in cultured fibroblasts with the 3243AB to G mutation in mitochondrial DNA. Biochim Biophys Acta 2000; 1500:10-16.
64. De La Asuncion JG, del Olmo ML, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 1998; 102:4-9.
65. Tennant BC, Baldwin BH, Graham LA, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B infection. Hepatology 1998; 28:179-191.
66. Brinkman K, Smeitink JA, Romijin JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
67. Melamed A, Muller RJ, Gold, J, et al. Possible Zidovudine-induced Hepatotoxicity. JAMA 1987; 258:2063.
68. Wallace DC. Diseases of mitochondrial DNA. Annu Rev Biochem 1992; 61:1175-1212.
69. Collins AR, Duthie SJ, Fillion L, et al. Oxidative DNA damage in human cells: the influence of antioxidants and DNA repair. Biochem Soc Trans 1997; 25:426-441.
70. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39(5):625-628.
71. Boxwell DE, Styrt BA. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs). 39th ICAAC, San Francisco, September 26-29, 1999. Abstract 1284.
72. Moore R, Keruly J, Chaisson R. Difference in anion gap with different RTI combinations. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 2000. Abstract 55.
73. Lonergan JT, Havlir D, Behling C, Pfander H, Hassanein T, Mathews WC. Hyperlactatemia in 20 patients receiving NRTI combination regimens. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 2000. Abstract 56.
74. 71a. Cote HG, Brumme ZL, Craib KJ, et al. NEJM 2002; 346:811-820.
75. Saint-Marc T, Touraine JL. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 1999; 13(15):2188—-2189.
76. Chodock R, Mylonakis E, Shemin D, Runarsdottir V, Yodice P, Renzi R, Tashima K, Towe C, Rich JD. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis—role of haemodialysis treatment. Nephrol Dial Transplant 1999; 14(10):2484-2486.
77. Scalfaro P, Chesaux JJ, Buchwalder PA, Biollaz J, Micheli JL. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intens Care Med 1998; 24:247-250.
78. Roy PM, Gouello JP, Pennison-Besnier I, Chennebault JM. Severe lactic acidosis induced by nucleoside analogues in an HIV-infected man. Ann Emerg Med 1999; 34(2):282-284.
79. Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta 1995; 1271:275-280.
80. Claessens YE, Cariou A, Chiche JD, Dauriat G, Dhainaut JF. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 2000; 14(4):472-473.
81. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with sta-vudine treatment in a HIV patient: a case report. AIDS 1997; 11(10):1294-1296.
82. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352(9124):291-292.
83. Luzzati R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavine and severe lactic acidosis. Lancet 1999; 353(9156):901-902.
84. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol 1999; 16(10):733-735.
85. Biour M, Poupon R, Grange JD, Chazouilleres O, Jaillon P. Hepatotoxicite des medicaments. Gastroenterol Clin Biol 2000; 24:1310-1351.
86. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998; 122:1256.
87. Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS 1998; 12:116-117.
88. Rutschmann OT, Negro F, Hirschel A, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus protease inhibitors on hepatitis C viremia in patients coinfected HIV. J Infect Dis 1998; 177:783-785.
89. 85a. Monforte A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. AIDS 2001; 28: 114-123.
90. Crowe S. New reverse transcriptase inhibitors. Adv Exp Med Biol 1999; 458:183-197.
91. Bissuel F, Habersetzer F, Chassard D, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994; 235:367-372.
92. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2', 3'-dideoxyinosine (ddI). Ann Intern Med 1991; 115:283-284.
93. Brivet FG, Nion I, Megarbane B, et al. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction. J Hepatol 2000; 32:364-365.
94. Allaouchiche B, Duflo F, Cotte I, et al. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy. J Antimicrob Chemother 1999; 44:137-138.
95. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306.
96. Mokrzycki M, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30:198-200.
97. Schiano TD, Lissoos TW, Ahmed A, et al. Lamivudine-induced liver failure in hepatitis B cirrhosis. Am J Gastroenterol 1997; 92:1563-1564.
98. Johri S, Alkhuja S, Siviglia G, Soni A. Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy. AIDS 2000; 14(9):1286-1287.
99. Miller K, Cameron M, Wood L, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133:192-196.
100. Ho TT, Wong KH, Chan KC, Lee SS. High incidence of lipodystrophy on a protease inhibitor-sparing highly antiretroviral therapy regimen. AIDS 2000; 14(4):468-469.
101. Anton P, Soriano V, Jimenez-Nacher I, et al. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS 1999; 13:524-525.
102. Cattelan AM, Erne E, Salatino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis 1999; 29(2):455-456.
103. Langlet P, Guillaume MP, Devriendt J, et al. Fatal liver failure associated with nevirapine in a pregnant HIV patient: the first reported case [abstract]. Gastroenterology 2000; 118: A6623.
104. Leitze Z, Nadeem A, Choudhary A, Saul Z, Roberts I, Manthous CA. Nevirapine-induced hepatitis treated with corticosteroids? AIDS 1998; 12:1115-1117.
105. Clarke S, Harrington P, Condon C, Kelleher D, Smith OP, Mulcahy F. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Intern J STD AIDS 2000; 11:336-337.
106. Prakash M, Poreddy V, Tiyyagura L, Bonacini M. Jaundice and hepatocellular damage associated with nevirapine therapy. Am J Gastroenterol 2001; 46:1571-1574.
107. Piroth L, Grappin M, Sgro C, Buisson M. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient. 2000; 34:534-535.
108. Ho TTY, Wong KH, Chan KCW, Lee SS. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS 1998; 12(15):2082-2083.
109. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures—worldwide, 1997-2000. MMWR 2001; 49(51):1153-1156.
110. 105a. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-803.
111. Brau N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997; 449:924-925.
112. Matsuda J, Gonani K, Yamanaka M. Severe hepatitis in patients with AIDS and hemophilia B treated with indinavir [letter]. Lancet 1997; 450:464.
113. Vergis E, Paterson L and Singh N. Indinavir-associated hepatitis in patients with advanced HIV infection. Int J STD AIDS 1998; 9:54.
114. Benveniste O, Longuet P, Duval X, et al. Two episodes of acute renal failure, rhabdomyolysis and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir. Clin Infect Dis 1999; 28:1180-1181.
115. Picard O, Rosmordue O, Cabane J. Hepatotoxicity associated with ritonavir. Ann Intern Med 1998; 129:670-671.
116. Keating MR. Antiviral agents for non-human immunodeficiency virus infections. Mayo Clin Proc 1999; 74:1266-1283.
117. Wedemeyer H, Boker KHW, Pethig K, et al. Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation 1999; 68:1503-1511.
118. Sacks SL, Wilson B. Famciclovir/penciclovir. Adv Exp Med Biol 1999; 458:135-147.
119. Ball AR. Valaciclovir update. Adv Exp Med Biol 1999; 458:149-157.
120. Renkes P, Trechot Ph, Blain H. Valaciclovir-induced hepatitis. Acta Clin Belg 1999; 54:17-18.
121. Aschan J, Ringden O, Ljungman P, Lonnqvist B, Ohlman S. Foscarnet for treatment of cytomegalovirus. Scand J Infect Dis 1992; 24:143-150.
122. Figge HL, Bailie GR, Briceland LL, Kowalsky SF. Possible ganciclovir-induced hepatotoxic-ity in patients with AIDS. Clin Pharm 1992; 11:432-434.
123. Shea BF, Hoffman S, Sesin GP, Hammer SM. Ganciclovir hepatotoxicity. Pharmacotherapy 1987; 7:223-226.
124. Kuypers D, Lau SG, Chapmen JR, Allen RDM. Hepatotoxicity in combined renal and pancreas allograft recipients treated with ganciclovir [abstract]. Immunol Cell Biol 1998; 76: A10.
125. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9:273-277.
126. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferon in cancer patients: a review. J Clin Oncol 1986; 4:234-243.
127. Atzpodien J, Lopez Hanninen E, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 1995; 13:497-501.
128. Gasparini G, Dal Fior S, Pozza F, et al. Phase I study of escalating dose mitoxantrone in combination with a-2-interferon in patients with advanced solid tumor. Invest New Drug 1991; 9:245-252.
129. Schomburg A, Kirchner H, Lopez-Hanninen E, et al. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-a. Am J Clin Oncol 1994; 17:199-209.
130. Gresser et al. Electrophoretically pure mouse interferon inhibits growth, induces liver and kidney lesions, and kills suckling mice. Am J Pathol 1981; 102:396-402.
131. Propst A, Propst T, Dietze O, Kathrein H, Judmeier G, Vogel W. Development of granulomatous hepatitis during treatment with interferon alfa-2b. Dig Dis Sci 1995; 40:2117-2118.
132. Veerabagu M, Finkelstein S, Rabinovitz M. Granulomatous hepatitis in a patient with chronic hepatitis C treated with interferon. Dig Dis Sci 1997; 42:(7)1445-1448.
133. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24:38-47.
134. Berris B, Feinman SV. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig Dis Sci 1991; 36:1657-1660.
135. Marcellin P, Colin J-F, Boyer N, et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet 1991; 338:828.
136. Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104:1116-1121.
137. Laskus T, Radkowski M, Slusarczyk J, Cianciara J. Severe exacerbation of chronic active hepatitis B during interferon alpha therapy. Digestion 1992; 52:61-64.
138. Ruiz-Moreno M, Rua MJ, Carreno V, et al. Autoimmune chronic hepatitis type 2 manifested during interferon therapy in children. J Hepatol 1991; 12:265-266.
139. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou J-P. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116:1.
140. Gschwantler M, Schrutka-Kolbl C, Weiss W. Acute exacerbation of antiliver cytosol antibody-positive autoimmune chronic hepatitis by a-interferon. Am J Gastroenterol 1995; 90:12.
141. Vento S, DiPerri G, Garofano T, et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 1989; 2:926.
142. Cervoni J-P, Degos F, Marcellin P, et al. Acute hepatitis induced by a-interferon, associated with viral clearance, in chronic hepatitis C. J Hepatol 1997; 27:1113-1116.
143. Shimizu Y, Shuji J, Akiharu W, et al. Hepatic Injury after interferon therapy for chronic hepatitis C [letter]. Ann Intern Med 1994; 121:723.
144. Villa E, Grottola A, Trande P, et al. Reactivation of hepatitis B virus infection induced by interferon (IFN) in HBsAg-positive, antiHCV-positive patients. Lancet 1993; 341:1413.
145. Durand JM, Kaplanski G, Portal I, Scheiner C, Berland Y, Soubeyrand J. Liver failure due to recombinant alpha interferon. Lancet 1991; 338:1268-1269.
146. Zoulim F, Trepo C. Nucleoside analogs in the treatment of chronic viral hepatitis: efficiency and complications. J Hepatol 1994; 21:142-144.
147. Mills J. Prevention and treatment of respiratory syncitial virus infections. Adv Exp Med Biol 1999; 458:39-53.
148. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-805.
149. Weissman SB, Sinclair GI, Green CL, Fissell WH. Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. J Infect Dis 1999; 29:223-224.
150. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokin 1998; 34:347-358.
151. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea for HIV infection. AIDS 1998; 12:F71-77.
152. Heddle R, Calvert AF. Hydroxyurea induced hepatitis. Med J Aust 1980; 1:121.
153. Chen SCA, Barker SM, Mitchell DH, et al. Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection. Pathology 1992; 24:109-111.
154. Acosta B, Grimsley EW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South Med J 1999; 92:421-423.
155. Freiman J, Helfert K, Hamrell M, et al. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993; 7:379-385.
156. Gradon JD, Chapnick EK, Sepkowitz DV. Zidovudine-induced hepatitis. J Intern Med 1992; 231:317-318.
157. Olano J, Borucki M, Wen J, et al. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 1995; 21:973-976.
158. Krishnamurthy S, Miguel S, Petra B, et al. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency. Crit Care Med 1997; 25:1425-1430.
159. Jolliet P, Widmann J-J. Reyes syndrome in an adult with AIDS. Lancet 1990; 335:1457.
160. Fortgang H, Belitsos PC, Chaisson RE, et al. Hepatomegaly and Steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995; 90: 1433-1436.
161. Chariot P, Drogou I, de-Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis and mitochondrial DNA depletion. J Hepatol 1999; 30:156-160.
162. Dubin G, Braffman MN. Zidovudine induced hepatotoxicity. Ann Intern Med 1989; 110: 85-86.